Italia markets close in 1 hour 26 minutes

FTSE MIB
34.766,76
+274,35(+0,80%)
Dow Jones
38.602,34
-83,98(-0,22%)
Nasdaq
16.840,05
+105,04(+0,63%)
Nikkei 225
38.923,03
+435,13(+1,13%)
Petrolio
74,97
-2,02(-2,62%)
Bitcoin EUR
64.253,84
+1.579,14(+2,52%)

NVCR Dec 2024 25.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

4,5000

0,0000

(0,00%)

In data: 11:16AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in